TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05301075
Drug: Rhomboid Intercostal and Sub-Serratus block
Normalized name: Fucus serratus extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rhomboid Intercostal and Sub-Serratus block under ultrasound guidance
Study: NCT06282315
Drug: Pre-screening Phase
Approvals — FDA: no, EMA: no, PMDA: no
Description: The entire school population will be invited to participate in the study. The purpose of this phase is to confirm participant eligibility for enrolment in the study based on the inclusion and exclusion criteria. Given the context in which the clinical trial is being conducted, in many instances, group meetings with the parents/guardians of potential participants in the community or at school might be necessary as part of the informed consent process. This consent process may be performed up to three months before the start of the screening visit activities.~Participants and parents/guardians of subjects will be asked to confirm in writing their agreement to participate in the trial before any study-specific procedure is conducted. In addition, written assent will be sought for participants over 12 years of age.
Study: NCT06282315
Drug: Screenig Phase
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The purpose of the screening visit is to confirm subject eligibility for enrolment in the study based on the inclusion/exclusion criteria. Screening visits in a particular school can be performed between 14 and 7 days before the intervention (Day 0).~To continue with the screening activities, participants must have signed written consent from their parent or legal guardian, and in the case of participants aged 12 years or older, they must also have a signed assent form before any specific study procedure is performed.If the consent/assent process has not been finalized during the pre-screening phase, this can be completed during the screening visit, but always before any trial procedure.~All participants who consent to participate in the trial will be given a Participant Screening Number, which will be assigned sequentially as the informed and assent forms are signed.
Study: NCT05940909
Drug: Perindopril/Indapamide/Amlodipine 8 mg/2.5 mg/10 mg tablet / Triplixam® 10 mg/2.5 mg/10 mg tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril/Indapamide/Amlodipine is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 8 mg of perindopril erbumine, 2.5 mg of indapamide and 10 mg of amlodipine.~Triplixam® is manufactured by Les Laboratoires Servier Industrie, France. Each tablet contains 10 mg of perindopril arginine, 2.5 mg of indapamide and 10 mg of amlodipine.
Study: NCT06282315
Drug: Baseline Effectiveness Cohort
Approvals — FDA: no, EMA: no, PMDA: no
Description: Before the administration of the study drug at school, participants selected for the Effectiveness Cohort will perform an additional study visit during which they will provide the study team with a stool sample for STH analysis. A dried blood spot (DBS) sample will also be taken to test for S. stercoralis.~Sampling of the baseline effectiveness cohort will be conducted within 7 days before the start of the school study intervention. In addition to the delivery of the stool/blood sample, participants from the effectiveness cohort will be evaluated for scabies by designated study personnel following the IACs simplified criteria.
Study: NCT06282315
Drug: Day 0 Trial Intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Within seven days after the first sample for the baseline effectiveness cohort is collected, the school's mass administration of the allocated drug will take place. All participants included in the list of eligible subjects from a particular randomized school will receive a single dose of the medication administered to their school (FDC or ALB). Before the administration, participants will be asked about any medical condition that has arisen since the last study visit, in which case information will be documented as a concomitant disease.~In case a participant vomits within one hour after the study drug intake (during the study physician observation period), the participant will continue participating in the trial and may still participate in the effectiveness cohort. If they are chosen for the day 21 or month 11 effectiveness cohort, an additional sensitivity analysis will be performed without including these participants, considered as Intervention Fail.
Study: NCT04783051
Drug: Pyramax
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent screening using ultra-sensitive malaria Rapid Diagnostic test and treatment using Pyronaridine - Artesunate (PYRAMAX®)
Study: NCT05707676
Drug: LB4330
Approvals — FDA: no, EMA: no, PMDA: no
Description: LB4330
Study: NCT06370754
Drug: JS001
Normalized name: Janus Kinase Inhibitor JS001
Approvals — FDA: no, EMA: no, PMDA: no
Description: 240 mg by IV infusionevery 3 weeks (Q3W), given on cycle day 1.
Study: NCT06370754
Drug: Leucovorin (LV)
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400mg/m\^2, intravenously, over 30 min on day 1, Q2W.
Study: NCT06282315
Drug: Passive Surveillance
Normalized name: RESPIRATORY TUBE 22MM PASSIVE R#1147378
Approvals — FDA: no, EMA: no, PMDA: no
Description: Passive surveillance will be carried out by monitoring AEs in health facilities near the schools involved in the study for six days after the intervention until Day 7 (end of the safety surveillance period). Although AE will be actively monitored during the scheduled study visits, this passive surveillance will allow for the identification of AEs and potential SAEs that might occur and remained underreported in case the participant does not attend school during the active safety surveillance period. In addition, a diary cards will be given to participants to write any AE they may have from Day 2 to Day 6 post intervention.
Study: NCT06282315
Drug: Post-Treatment Effectiveness Evaluation
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Post-treatment effectiveness evaluation will be performed by measuring the prevalence of STH at two time points: 21 days after the intervention (± 7 days) and 11 months after intervention (± 28 days). Additionally, the reduction in S. stercoralis seroprevalence will be evaluated 11 months after the intervention.~These participants will be tested for STH by Kato-Katz at the two post-treatment time points (day 21 and month 11) and for S. stercoralis by NIE ELISA at 11 months. The diagnostic test will be the same as in the intervention of Baseline Effectiveness Cohort.~As part of the genetic monitoring pilot study and the microbiome analysis, the same samples will be collected as described in the intervection of Baseline Effectiveness Cohort.
Study: NCT05837156
Drug: Heptaflurane combined Cyclophenol
Normalized name: apaflurane
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heptaflurane combined Cyclophenol
Study: NCT05837156
Drug: Heptaflurane
Normalized name: apaflurane
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heptaflurane only
Study: NCT05837156
Drug: Cyclophenol
Normalized name: CYCLOPHENE KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophenol only
Study: NCT05541276
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Melatonin for injection 1 mg/mL
Study: NCT05834738
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05818852
Drug: VX-548 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets for oral administration.
Study: NCT06506175
Drug: HRS9531 tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRS9531 tablets
Study: NCT05352815
Drug: IcoSema
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive once weekly IcoSema subcutanously (s.c. under the skin) with or without oral anti diabetic drugs for 52 weeks.
Study: NCT05873881
Drug: Thiamine Mononitrate 300 mg
Normalized name: Thiamine Mononitrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiamine Mononitrate 300 mg daily
Study: NCT06569394
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants in this Arm will take a medically inert placebo. Participants will take medication by mouth with food in the morning and evening.
Study: NCT06560515
Drug: Vaginal Dinoprostone
Normalized name: dinoprostone Vaginal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: induction of labour in women with postdate pregnancy with vaginal dinoprostone vs. vaginal misoprostol
Study: NCT05666336
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: It is permitted which can be interchangeable with mycophenolate mofetil or tacrolimus. It will be given by oral administration of 0.8g/month for 24 weeks.
Study: NCT02712151
Drug: Sterile saline
Normalized name: Aqua Care Sterile Saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injection
Study: NCT06324006
Drug: LIB-01
Approvals — FDA: no, EMA: no, PMDA: no
Description: LIB-01 oral suspension
Study: NCT04878770
Drug: Topical corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical corticosteroids (TCS) are registered for patients of all ages, and are together with emollients, the pillars in the basic treatment of atopic dermatitis. In this study, patients in both the intervention groups and control group are treated with daily emollients and a TCS of moderate to high potency if needed. Rescue medication with TCS of higher potency may be prescribed if basic therapy is inadequate in controlling AD symptoms.
Study: NCT05010122
Drug: Decitabine and Cedazuridine
Normalized name: cedazuridine / decitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT05877053
Drug: Placebo for CK-4021586
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for CK-4021586
Study: NCT04728061
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenously-infused vehicle.
Study: NCT05492630
Drug: HEC73077 tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-Dose Study: Each dose of HEC73077 and placebo will be administered with approximately 240 mL of water in the morning after fasting for at least 10 hours overnight.~Multiple-dose study:The study doses, administration method (fasted or fed), dosing frequency, and dosing period are all to be determined based on data from the single-dose study and/or multiple-dose study.
Study: NCT05492630
Drug: HEC73077 placebo tablets
Normalized name: PLACEBO TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-Dose Study: Each dose of HEC73077 and placebo will be administered with approximately 240 mL of water in the morning after fasting for at least 10 hours overnight.~Multiple-dose study:The study doses, administration method (fasted or fed), dosing frequency, and dosing period are all to be determined based on data from the single-dose study and/or multiple-dose study.
Study: NCT05589792
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo before sleep for 3 nights before the study (inclusive)
Study: NCT05375604
Drug: CDK-004
Normalized name: Cyclin-dependent kinase (CDK) inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASO-STAT6 exosome administered Intravenously
Study: NCT01422148
Drug: Minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravenous minocycline 100 mg daily x 5 days starting intra-operatively combined with oral amiodarone (400 mg twice daily for 7 days, then 200 mg twice daily for the next 7 days
Study: NCT05651126
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive placebo
Study: NCT05354583
Drug: Appropriate treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with at least 3 antibiotics, which the pathogen is susceptible to based on in vitro drug susceptibility test, in the initial phase of the treatment
Study: NCT04845321
Drug: VNRX-9945
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part 1: One dose except food effect cohort (receives two doses) Part 2: 14 doses (once a day for 14 days)
Study: NCT04845321
Drug: Placebo for VNRX-9945
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part 1: One dose except food effect cohort (receives two doses) Part 2: 14 doses (once a day for 14 days)
Study: NCT04188574
Drug: BB2603-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with topical spray twice-daily (BID) BB2603-1: 0.01% terbinafine
Study: NCT04188574
Drug: BB2603-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with topical spray twice-daily (BID) BB2603-10: 0.1% terbinafine
Study: NCT01268709
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05068466
Drug: INCB054707
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered Orally
Study: NCT05068466
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered Orally
Study: NCT05040880
Drug: Telmione plus 80/12.5mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test drug (Fixed-dose combination drug of telmisartan 80mg and hydrochlorothiazide 12.5mg)
Study: NCT05040880
Drug: Micardis plus 80/12.5mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference drug (Fixed-dose combination drug of telmisartan 80mg and hydrochlorothiazide 12.5mg)
Study: NCT00000171
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00433225
Drug: Prednisolone Acetate
Normalized name: Prednisolone Acetate
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00433225
Drug: Ketorolac 0.4%
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05442151
Drug: PET/CT ([F-18]FAPI-74)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PET/CT using \[18F\] FAPI-74 injection
Study: NCT05965492
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day 1 and Day 2: 1000 mg three times a day administered via tablet by mouth for a total cumulative daily dose of 3000 mg.~Day 3 and Day 4: 825 mg three times a day administered via tablet by mouth for a total cumulative daily dose of 2475 mg.~Day 5: 500 mg two times a day and 325 mg once a day administered via tablet by mouth for a total cumulative daily dose of 1325 mg.~Day 6: 500 mg once a day and 325mg twice a day administered via tablet by mouth for a total cumulative daily dose of 1150 mg.~Day 7: 500 mg twice a day administered via tablet by mouth for a total cumulative daily dose of 1000 mg.
Study: NCT06353061
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: The dosage of cisplatin is 40 mg/m2, administered once weekly during radiotherapy for a duration of 5 weeks. Prior to and following cisplatin administration, 1-2 liters of fluid should be given for adequate hydration. Treatment should continue until disease progression or intolerable toxicity occurs.
Study: NCT04093505
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consolidation \& Maintenance therapy Placebo 100mg on days 4 to 27
Study: NCT06278545
Drug: modified FOLFORINOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: One treatment every 14 days :~* Irinotecan 180mg/m² as a 2-hour IV infusion~* Oxaliplatin 85 mg/m² as a 2-hour IV infusion~* Folinic acid 400 mg/m² as 2-hour IV infusion, in Y with oxaliplatin~* 5-FU 2400 mg/m² as a continuous IV infusion over 46 hours
Study: NCT06278545
Drug: Modified FOLFOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: One treatment every 14 days:~* Oxaliplatin 85 mg/m by IV infusion over 2 hours~* Folinic acid: 400 mg/m² or 200 mg/m² if laevorotatory form by IV infusion over 2 hours, in Y with oxaliplatin~* 5FU bolus: 400 mg/m² per 10-minute IV infusion~* 5 FU continuous 2400 mg/m² by IV infusion over 46 hours
Study: NCT05636592
Drug: immunotherapy
Normalized name: Dog immunotherapy extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: statin combined with immunotherapy
Study: NCT06231745
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX) is an anti-metabolite most commonly used in chemotherapy and immunosuppressant in auto-immune diseases. This activity describes the indications, action, and contraindications for Methotrexate as a valuable agent in treating a wide variety of diseases.
Study: NCT06439212
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient will receive one capsule of placebo thrice daily for two days. First dose will be administered 1 hour before starting endodontic treatment.
Study: NCT05121480
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral capsule
Study: NCT05867615
Drug: [177Lu]Lu-PSMA I&T
Approvals — FDA: no, EMA: no, PMDA: no
Description: 177Lu activity to be administered to single patient (range 5.5-7.4 GBq), every 8 weeks (±2 weeks) will be measured in a dose calibrator, properly calibrated for the radionuclide. The radiopharmaceutical will be slowly infused intravenously over 15-30' in a dedicated room using a dedicated pump system.
Study: NCT05685173
Drug: REGN5837
Approvals — FDA: no, EMA: no, PMDA: no
Description: REGN5837 will be administered by IV infusion
Study: NCT04775745
Drug: LP-168
Normalized name: LP-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: For the dose escalation phase, LP-168 will be given once or twice daily at the following dose levels:100 mg QD,150 mg QD, 100 mg BID, 300 mg QD, 150 mg BID, 450 mg QD, 225 mg BID, 600 mg QD, 800 mg QD, and 1000 mg QD.
Study: NCT04775745
Drug: LP-168
Normalized name: LP-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: For the dose expansion phase, subjects will receive once or twice daily dose of LP-168 at the Recommended Phase 2 Dose (RP2D). The RP2D may be as high as the MTD and will be determined following evaluation of Phase I Dose Escalation results.
Study: NCT05472467
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Squamous carcinoma: docetaxel 60 mg/m2, d1 + cisplatin 25 mg/m2, d1-3 or carboplatin AUC=4-6 d1, 21 days for one cycle, up to 4 cycles.~Non-squamous carcinoma: pemetrexed 500 mg/m2, d1 + cisplatin 25 mg/m2, d1-3 or carboplatin AUC=4-6, d1,21 days for one cycle, up to 4 cycles.
Study: NCT05955105
Drug: ILB-2109
Approvals — FDA: no, EMA: no, PMDA: no
Description: ILB-2109 tablets will be administered by mouth every day in 21-day cycles
Study: NCT06284746
Drug: Tirolizumab+SOX/XELOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tirolizumab combined with chemotherapy(SOX/XELOX) regimen. The SOX regimen consists of the drugs Tegilol (S-1) and Oxaliplatin. The XELOX regimen consists of the drugs oxaliplatin and capecitabine.
Study: NCT06284746
Drug: SOX/XELOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simple chemotherapy regimen (SOX/XELOX regimen). The SOX regimen consists of the drugs Tegilol (S-1) and Oxaliplatin. The XELOX regimen consists of the drugs oxaliplatin and capecitabine.
Study: NCT04480086
Drug: Mivebresib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet: Oral
Study: NCT05414981
Drug: ABI-H3733
Normalized name: PICEA ABIES WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg or 100 mg tablets for oral administration
Study: NCT05414981
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg or 100 mg tablets for oral administration
Study: NCT06353828
Drug: CBD, synthetic form
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cannabidiol enema
Study: NCT06353828
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo enema
Study: NCT06287229
Drug: Hyper-CVAD
Normalized name: Hyper-Sal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given by IV Participants younger than 60 years of age, you will receive hyper-CVAD.
Study: NCT06287229
Drug: Mini-hyper-CVD
Normalized name: Hyper-Sal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given by IV Participants 60 years of age or older, you will receive mini-hyper-CVD
Study: NCT05330325
Drug: Norditropin®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norditropin® will be administered s.c. once daily using FlexPro® pen-injector.
Study: NCT06273891
Drug: Erythromycin
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erythromycin 250 mg IV every 6 hours for 48 hours, followed by 250 mg PO or 333 mg PO every 8 hours for 5 days~in addition to Ampicillin 2 gm IV every 6 hours for 2 days followed by Amoxicillin 250 mg PO every 8 hours for 5 days
Study: NCT06273891
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin 1 gm PO once or 500 mg PO followed by 250 mg PO daily for a total of 5 days~in addition to Ampicillin 2 gm IV every 6 hours for 2 days followed by Amoxicillin 250 mg PO every 8 hours for 5 days
Study: NCT00002318
Drug: Doxorubicin hydrochloride (liposomal)
Normalized name: DOXORUBICIN HYDROCHLORIDE LIPOSOME
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002318
Drug: Doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04764214
Drug: 3rd generation EGFR-TKI
Normalized name: celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Osimertinib will be administered orally at the dose of 80 mg once daily.
Study: NCT05428943
Drug: OPT101
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15-mer peptide derived from the sequence of mouse CD154.
Study: NCT05663411
Drug: SHR6508
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR6508
Study: NCT06461975
Drug: artificial tear (Sodium Hyaluronate 2 mg/ml) eye drops.
Approvals — FDA: no, EMA: no, PMDA: no
Description: The second group had the first examination done using the Benoxinate HCL drops Benox ® eye drops and the second using the tear substitute Polyfresh ®given just before the ROP screening.
Study: NCT05877430
Drug: CJRB-101
Approvals — FDA: no, EMA: no, PMDA: no
Description: In Phase 1, one or two capsules of CJRB-101 will be given every day. In Phase 2, the CJRB-101 dose selected from Phase 1 will be given every day.
Study: NCT05526443
Drug: all approved chemotherapeutic agents from second line
Approvals — FDA: no, EMA: no, PMDA: no
Description: all approved chemotherapeutic agents from second line
Study: NCT04724460
Drug: Long DOAC
Normalized name: long pepper extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of Rivaroxaban for 18 months
Study: NCT06381466
Drug: AZD0233
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized participants will receive AZD0233 orally as a single ascending dose (dose 1, dose 2, dose 3, dose 4 or dose 5) or multiple ascending dose (dose 6, dose 7 or dose 8)
Study: NCT06381466
Drug: AZD0233 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized participants will receive matching placebo orally as a SAD or MAD.
Study: NCT05896384
Drug: Microgynon®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethinylestradiol (EE) and Levonorgestrel (LNG)
Study: NCT05357690
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL of saline injected in the plane of the right stellate ganglion